How are NVAX strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NVAX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 82.83%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$129.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a NVAX strangle?

The breakeven for the NVAX strangle priced on this page is roughly $7.21 and $10.79 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NVAX market-implied 1-standard-deviation expected move is approximately 23.75%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current NVAX implied volatility affect this strangle?

NVAX ATM IV is at 82.83% with IV rank near 27.79%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

NVAX Strangle Strategy

NVAX (Novavax, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

NVAX (Novavax, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.46B, a beta of 2.41 versus the broader market, a 52-week range of 6.2-11.97, average daily share volume of 4.8M, a public-listing history dating back to 1995, approximately 952 full-time employees. These structural characteristics shape how NVAX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.41 indicates NVAX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on NVAX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current NVAX snapshot

As of June 29, 2026, spot at $9.18, ATM IV 82.83%, IV rank 27.79%, expected move 23.75%. The strangle on NVAX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 32-day expiry.

Why this strangle structure on NVAX specifically: NVAX IV at 82.83% is on the cheap side of its 1-year range, which favors premium-buying structures like a NVAX strangle, with a market-implied 1-standard-deviation move of approximately 23.75% (roughly $2.18 on the underlying). The 32-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NVAX expiries trade a higher absolute premium for lower per-day decay. Position sizing on NVAX should anchor to the underlying notional of $9.18 per share and to the trader's directional view on NVAX stock.

NVAX strangle setup

The NVAX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NVAX near $9.18, the first option leg uses a $9.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NVAX chain at a 32-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NVAX shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$9.50	$0.70
Buy 1	Put	$8.50	$0.59

NVAX strangle risk and reward

Net Premium / Debit: -$129.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$129.00
Breakeven(s): $7.21, $10.79
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

NVAX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on NVAX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$720.00
$2.04	-77.8%	+$517.14
$4.07	-55.7%	+$314.27
$6.10	-33.6%	+$111.41
$8.12	-11.5%	-$91.46
$10.15	+10.6%	-$63.68
$12.18	+32.7%	+$139.19
$14.21	+54.8%	+$342.05
$16.24	+76.9%	+$544.91
$18.27	+99.0%	+$747.78

When traders use strangle on NVAX

Strangles on NVAX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NVAX chain.

NVAX thesis for this strangle

The market-implied 1-standard-deviation range for NVAX extends from approximately $7.00 on the downside to $11.36 on the upside. A NVAX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NVAX IV rank near 27.79% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NVAX at 82.83%. As a Healthcare name, NVAX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NVAX-specific events.

NVAX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NVAX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NVAX alongside the broader basket even when NVAX-specific fundamentals are unchanged. Always rebuild the position from current NVAX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on NVAX?: A strangle on NVAX is the strangle strategy applied to NVAX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NVAX stock trading near $9.18, the strikes shown on this page are snapped to the nearest listed NVAX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are NVAX strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NVAX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 82.83%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$129.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a NVAX strangle?: The breakeven for the NVAX strangle priced on this page is roughly $7.21 and $10.79 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NVAX market-implied 1-standard-deviation expected move is approximately 23.75%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on NVAX?: Strangles on NVAX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NVAX chain.
How does current NVAX implied volatility affect this strangle?: NVAX ATM IV is at 82.83% with IV rank near 27.79%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.